Yoni Freedhoff

@yonifreedhoff.bsky.social

Associate Professor of Family Medicine @UOttawa/Exclusively obesity medicine since 2004/Bylines spanning from The Lancet to the NYTs/הנני

Decided I'm going to write an add-on for my book for the GLP1 era. Just as with dieting, so much misinformation around GLP1s and this addition very much inline with book's overarching aim to mythbust and to make ending traumatic dieting that much more doable. Hope to have available by January

Had a nice chat with @caitlinschiller about my now vintage book The Diet Fix. Book holds up imo, but needs a chapter on permission to use GLP1s and mythbusting around them. The title btw wasn't my choice. Mine was, "A Prescription for Chocolate: The End of Traumatic Dieting". Can have a listen here:

Eat chocolate and enjoy life: a practical diet framework

Dr. Yoni Freedhoff on what having a "best weight" actually means

simplify-show.beehiiv.com

My latest in @medscape.com on how obesity is finally, truly, a choice. But no, not the choice of trying harder, but rather of therapeutics, where even our current generation of medications and surgeries, if accessible and affordable to all, would push 90% of obesity into remission

My latest in @medscape.com: Seems that one by one the fear mongered risks about GLP1s get disproven. No increased suicide risk, no thyroid cancer risk, no blindness risk. But the loudest these days is muscle loss risk. Well guess what? No meaningful risk there either www.medscape.com/viewarticle/...

No Need to Worry About GLP-1-Induced Muscle Loss

Recent headlines have alarmingly stated dramatic muscle loss for patients on GLP-1s. Yoni Freedhoff, MD, explains why this is a manufactured controversy.

medscape.com

My latest on @medscape.com on how declining obesity rates are now almost certainly attributable to GLP-1 medications, but how new guidelines meant to be wiser than BMI in its diagnosis are apparently diagnosing 70% of the population with obesity www.medscape.com/viewarticle/...

We’re Curing Obesity, But Far More People Apparently Have It

Recent reports show a decrease in obesity rates; however, a new proposed definition predicts a surge of people with obesity.

medscape.com

My latest in @medscape.com on GLP1 meds and suicide: Did you hear GLP1 meds might increase the risk of suicide? I'd bet you did. It was all over the news consequent to just 3 case reports submitted by Iceland to the European Medicine Association who announced an investigation /1

@yonifreedhoff.com Here are violin plots showing distribution of the ww signal in Ottawa by year and by VOC. "wwlast30d" represents signal sampled over past 30 days. A 5-year, continuous public health dataset unaffected by policy changes--unlike clinical indicators--is a beautiful thing.

2 plots showing distributions of ww signal by year and by VOC.

You might remember my blog on how Lilly effectively levied a fat tax on obesity whereby they were charging more for tirzepatide prescribed for obesity than for diabetes in 🇨🇦. Well they've cancelled that and launched a financial assistance program for Zepbound open.substack.com/pub/yonifree...

Lilly Cancels Its Tirzepatide Fat Tax

Lilly announces the pending launch of their MyZepbound.ca financial assistance program for patients prescribed tirzepatide for obesity

open.substack.com

Good news for Canadians looking to start Zepbound (tirzepatide) for obesity. Lilly will be introducing a program to help defray costs. Medication should be on shelves mid summer. I'll blog about this in more detail but wanted to briefly mention

My latest for @Medscape asking why, despite robust evidence demonstrating sustained weight loss significantly decreases both cancer incidence and recurrence that both patient and doctor facing literature on same nearly never mention it? /1

It seems it's now official. Lilly has effectively levied a fat tax on Canadian prescriptions of its diabetes and obesity medication tirzepatide (aka Mounjaro/Zepbound) whereby if prescribed for obesity, you'll pay nearly double what you'd pay if prescribed for diabetes. More in my Substack

Despite Assurances To The Contrary, Lilly Has Effectively Levied A Fat Tax In Canada For Mounjaro

If You Have Obesity, You'll Pay Nearly Double For Mounjaro Than If You Have Diabetes

open.substack.com

My latest on Medscape covers a recently published study that both traditional media and social media reported as being proof that Splenda increases hunger (and of course as a consequence, increases weight). Sounds scary. Unless you actually read the paper 🧵

My latest in Medscape discusses 3 recent examples of how studies regarding obesity that ignore obesity medications, despite their being our current standard of care in obesity's treatment, do a disservice to readers, reporters, and the public. www.medscape.com/viewarticle/...

Don’t Bash the Usefulness of Obesity Medicines

Recent studies offer a grim view of obesity treatment, however, they fail to acknowledge the current generation of obesity medications. Yoni Freedhoff, MD, explains why this is problematic.

medscape.com

Ottawa WAVE (Wastewater Analytics for Viral Epidemiology) as of Mar 16. LEFT IMAGE: 7d trendline of SARS-CoV-2 signal since spring 2020 (A); Past year (B), and 2 months (C), inferred case incidence (D), and Reff (E) determined with ern (PMID: 38905266). RIGHT IMAGE: other viral traces

Plots of SARS-CoV-2 signal across time in Ottawa, Canada;Plots of IAV, RSV, IBV, MPOX wastewater signal across time in Ottawa, Canada;

My latest, published ahead of print in the Canadian Journal of Cardiology looks at the historic failure of public health to move the needle on chronic non-communicable diseases like obesity, and its historic opportunity now to find some success /🧵